Genetic Variations In Enzymes That Metabolize Drugs Contribute To Cancer Risk, Find University Of Pittsburgh Researchers

April 14, 1997

San Diego, April 10 -- Naturally occurring genetic variations in drug metabolizing enzymes significantly contribute to whether a person develops certain cancers, according to recent studies by University of Pittsburgh investigators who are presenting their findings at the annual meeting of the American Association for Cancer Research.

These enzymes, called cytochrome P450s (CYPs) and phase II enzymes, normally metabolize, or breakdown, chemicals entering the body. Slight variations in the gene for a given enzyme result in different forms of that enzyme, each form performing the same function but at a different rate. Because of these genetic differences, individuals metabolize foreign substances differently from one another.

"Individuals with certain genetic profiles or a history of certain environmental exposures are strongly at risk for head and neck cancer," said Marjorie Romkes, Ph.D., assistant professor of environmental and occupational health and toxicology. Elevated activity of one enzyme (CYP2E1), low activity of another (CYP2C19), smoking, alcohol consumption and occupational exposures independently place individuals at increased risk for head and neck cancer, according to preliminary findings comparing 40 head and neck cancer patients with 85 cancer-free controls.

"Certain enzyme genotypes in people without cancer appear to be associated with DNA damage that could lead to cancer," said Dr. Romkes in regard to another presentation showing that normal human cells with certain enzyme forms showed higher levels of DNA mutations than human cells with different enzyme forms.

Another ongoing collaborative research project with Phouthone Keohavong, Ph.D., indicates that individuals with bladder cancer who had p53 mutations either had a history of exposure to a cancer-causing substance or abnormalities in enzymes that process environmental chemicals. p53 is a gene that normally suppresses tumor growth. When mutated, the p53 gene cannot function correctly and cancer arises. p53 mutations are suspected to be involved in about half of all cancers.

Some CYPs remove cancer-causing agents by turning them into benign chemicals within the body. Researchers aim to develop drugs that would accelerate the activity of these enzymes in patients whose enzymes naturally work very slowly. Other CYPs do the reverse, taking procarcinogens (potentially cancer-causing substances) and turning them into cancer-causing chemicals that linger in the body where they can cause damage. The Pitt investigators are working with drugs to block or slow the activity of these enzymes in individuals who have enzymes that rapidly produce such cancer-causing substances.

Other collaborators on these studies include Robert Branch, M.D.; Adedayo Adedoyin, Ph.D.; Cheri White; Regie Frye, Ph.D.; Jonas Johnson, M.D.; David Eibling, M.D.; Barb Henry; Gilberto Fregoso, M.D.; William L. Bigbee, Ph.D.; Rob Gealy; Alea Melacrino; Herng der Chern, M.D.; and Raj Persad, M.D.
-end-
lk\4-11-97

University of Pittsburgh Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.